IL317679A - Methods for treating previously untreated follicular lymphoma with mosunatuzumab and nalididomide - Google Patents
Methods for treating previously untreated follicular lymphoma with mosunatuzumab and nalididomideInfo
- Publication number
- IL317679A IL317679A IL317679A IL31767924A IL317679A IL 317679 A IL317679 A IL 317679A IL 317679 A IL317679 A IL 317679A IL 31767924 A IL31767924 A IL 31767924A IL 317679 A IL317679 A IL 317679A
- Authority
- IL
- Israel
- Prior art keywords
- dose
- mosunetuzumab
- administered
- dosing cycle
- rasburicase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263354491P | 2022-06-22 | 2022-06-22 | |
| PCT/US2023/068804 WO2023250367A1 (en) | 2022-06-22 | 2023-06-21 | Methods for treatment of previously untreated follicular lymphoma with mosunetuzumab and lenalidomide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL317679A true IL317679A (en) | 2025-02-01 |
Family
ID=87519897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL317679A IL317679A (en) | 2022-06-22 | 2023-06-21 | Methods for treating previously untreated follicular lymphoma with mosunatuzumab and nalididomide |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240043553A1 (https=) |
| EP (1) | EP4543546A1 (https=) |
| JP (1) | JP2025521501A (https=) |
| KR (1) | KR20250025678A (https=) |
| CN (1) | CN119546334A (https=) |
| AU (1) | AU2023286618A1 (https=) |
| CA (1) | CA3259327A1 (https=) |
| IL (1) | IL317679A (https=) |
| MX (1) | MX2024015750A (https=) |
| TW (1) | TWI881370B (https=) |
| WO (1) | WO2023250367A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026009843A (ja) * | 2024-06-25 | 2026-01-21 | ジェネンテック， インコーポレイテッド | 単剤療法としてまたはレナリドミドと組み合わせたモスネツズマブの皮下投与を用いてがんを処置する方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CA3190376A1 (en) * | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| JP7716473B2 (ja) * | 2020-11-04 | 2025-07-31 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬 |
| TWI874719B (zh) * | 2020-11-04 | 2025-03-01 | 美商建南德克公司 | 用抗cd20/抗cd3雙特異性抗體進行治療之給藥 |
-
2023
- 2023-06-21 EP EP23748657.6A patent/EP4543546A1/en active Pending
- 2023-06-21 KR KR1020257000914A patent/KR20250025678A/ko active Pending
- 2023-06-21 CA CA3259327A patent/CA3259327A1/en active Pending
- 2023-06-21 JP JP2024574565A patent/JP2025521501A/ja active Pending
- 2023-06-21 CN CN202380047723.4A patent/CN119546334A/zh active Pending
- 2023-06-21 WO PCT/US2023/068804 patent/WO2023250367A1/en not_active Ceased
- 2023-06-21 TW TW112123338A patent/TWI881370B/zh active
- 2023-06-21 US US18/338,985 patent/US20240043553A1/en active Pending
- 2023-06-21 IL IL317679A patent/IL317679A/en unknown
- 2023-06-21 AU AU2023286618A patent/AU2023286618A1/en active Pending
-
2024
- 2024-12-17 MX MX2024015750A patent/MX2024015750A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN119546334A (zh) | 2025-02-28 |
| US20240043553A1 (en) | 2024-02-08 |
| KR20250025678A (ko) | 2025-02-24 |
| EP4543546A1 (en) | 2025-04-30 |
| CA3259327A1 (en) | 2023-12-28 |
| AU2023286618A1 (en) | 2025-01-09 |
| MX2024015750A (es) | 2025-02-10 |
| WO2023250367A1 (en) | 2023-12-28 |
| TWI881370B (zh) | 2025-04-21 |
| TW202409075A (zh) | 2024-03-01 |
| JP2025521501A (ja) | 2025-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Markman | Managing taxane toxicities | |
| Roila et al. | Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. | |
| Gottlieb et al. | Chemotherapy of malignant lymphoma with adriamycin | |
| Rowinsky | Update on the antitumor activity of paclitaxel in clinical trials | |
| IL317679A (en) | Methods for treating previously untreated follicular lymphoma with mosunatuzumab and nalididomide | |
| EP0433765A1 (en) | The use of immunomodulants as synergistic agents of chemotherapeutics in tumor therapy | |
| Ferrara et al. | Vincristine as salvage treatment for refractory thrombotic thrombocytopenic purpura | |
| MX2022013391A (es) | Pauta posologica para el tratamiento del cancer. | |
| JPS62145029A (ja) | インタ−フエロン組成物 | |
| Frakes et al. | An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant | |
| JP2025521501A5 (https=) | ||
| IL317954A (en) | Treatment of hematological malignancies with galectin-9 inhibitory antibodies | |
| US5756514A (en) | Methods for treatment and prevention of drug-induced pruritus with serotonin type 3 receptor antagonists | |
| Cersosimo et al. | Acute hypotensive reaction to etoposide with successful rechallenge: case report and review of the literature | |
| Suzuki et al. | Primary plasma cell leukemia: a case report of successful responder to a combination chemotherapy of vincristine, doxorubicin and dexamethasone | |
| Adamczyk et al. | A 12-year old girl with severe plaque psoriasis and Down syndrome treated successfuly with etanercept | |
| RU2024139114A (ru) | Способы лечения ранее нелеченной фолликулярной лимфомы с помощью мосунетузумаба и леналидомида | |
| Petrova et al. | Efficacy and safety of SGLT2 inhibitors in patients with type 2 diabetes mellitus: a systematic review | |
| Avanzini et al. | INSIGHT and NORDIL | |
| Sanborn et al. | Efficacy of dacarbazine (DTIC) in preventing metastases arising from intraocular melanomas in mice | |
| Puig | Treatment of severe psoriasis | |
| Gorschlüter et al. | Successful induction and consolidation therapy of acute myeloid leukaemia in a renal allograft recipient. | |
| Komada et al. | Discontinuing therapy in childhood acute lymphoblastic leukemia treated with a chemoimmunotherapy protocol | |
| Bichel et al. | Treatment of pruritus in Hodgkin's disease and in reticulum cell sarcoma | |
| Roila et al. | Antiemetic activity of two different high doses and schedules of metoclopramide in dacarbazine-treated cancer patients |